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fd. Note - This overview was originally presented at the 
International Symposium on Clinical Disorders of Bone 
and Mineral Metabolism, May 9-13,1983. The following 
list indicates the presentations given in this session at the 
Symposium and the contents ofthe corresponding chap-
ter in the Proceedings of the Symposium published by 
Excerpta Medica. The numbers in parentheses refer to 
pages in this volume. Complete information about the 
contents of the Proceedings can be found at the back of 
this issue. 
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Vilanueva, D.S. Rao, M. Rogers, M. Kleerekoper, and B. 
Frame (328) 
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for two distinct osteoporosis syndromes. B.L. Riggs, L.J. 
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Can estrogen therapy prevent bone loss? R. Lindsay (346) 
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Anabol ic steroids and calcitonin in the treatment of 
postmenopausal osteoporosis. C H . Chesnut 111, D.J. Bay-
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K. Sisom (355) 
Treatment of idiopathic osteoporosis with sodium fluo-
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The use of calcitrol (1,25 dihydroxyvitamin D) in osteo-
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Pathogenesis 
Osteoporos is is the most common of the metabolic 
bone diseases. A number of papers presented at this 
symposium have indicated the progress made in this 
f ield, relating both to the pathogenesis of the disease 
and to its prevention and treatment. 
Nord in , et al (pp. 323 ff.) reported additional data to 
support their model for the determination of bone 
volume by an independent variable (bone formation 
rate) and a volume-dependent variable (fractional bone 
resorption). In this case, mean-seam width was used as 
an index of formation in biopsies from a group of pre-
menopausal women in a state of equi l ibr ium, when for-
mation and resorption are balanced. Again, previously 
reported correlations were found. Nordin feels that age-
related bone loss is associated with an increase in resorp-
t ion, which is more marked in those who develop osteo-
porosis. The principal disagreement here is with the 
methods used to estimate rates of resorption and bone 
formation—measurement of resorption and formation 
surfaces. Many investigators feel that rates cannot be 
derived from staticsurface measurements. Nordin empha-
sizes the importance of the model or formation as an 
independent variable, and believes that substitution of 
other measures (i.e., the calcification rate derived from 
tetracycline labeling) would only shift the curve and 
would not alter the fundamental concept. Clearly, addi-
tional data using mult iple methods to correlate change 
over time will be needed to resolve this dilemma. 
Parfitt, et al (p. 328 ff.) addressed the important problem 
of age-related loss of trabecular bone f rom a new per-
spective. Is this loss of trabecular bonedue toa decrease 
in the number (density) of tra beeu lae or to a decrease in 
the thickness of individual trabeculae? His studies indi-
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cate that both mechanisms are in part responsible, but 
loss of trabeculae is the predominant mechanism, both 
for age-related loss and for the more marked deficit 
found among osteoporotics. A reduction in the mean-
wall thickness of individual structural units can explain 
the thinness of indiv ldual trabeculae but not total lossof 
the structure. He suggests that during the accelerated 
phase of bone loss, shortly after menopause, osteoclasts 
perforate trabeculae; thus, there is no remaining struc-
ture upon which new bone can be rebuilt. A similar 
mechanism may be responsible for endosteal bone loss. 
Studies util izing tetracycline labeling as a measure of 
bone apposition indicate that osteoblast function declines 
with age in normal individuals and, to a more marked 
degree, in osteoporotics. After menopause, the increase 
in bone remodeling persists for some time. Among some 
who will develop osteoporosis, the rapid remodeling 
ceases for unknown reasons, and this cessation may be an 
important factor in fracture pathogenesis. He suggests 
that some osteoporotics start with low bone mass at 
maturity and have a prolonged phase of accelerated bone 
loss, the result of which is low bone mass and fracture. 
These individuals would have high remodeling on biop-
sies taken at the time of fracture. Others have rapid loss 
but are unable to compensate, and decreased remodel-
ing is found on biopsy. Thus, the heterogeneity of mor-
phometric variables in osteoporosis can be explained. 
Parfitt presented a new hypothesis which places great 
emphasis on loss of structural elements due to increased 
osteoclast activity. Because this phenomenon occurs 
years before fracture, prevention and treatment must 
focus on the years associated with rapid bone loss, 
shortly after the menopause. Nordin stressed increased 
resorption as the primary event responsible for bone loss 
in osteoporosis. Measured variables are derived from 
static measurement of bone surfaces at the t ime of frac-
ture. Parfitt emphasized that most o f the bone loss is due 
to removal of structural elements during the rapid phase 
of bone loss after the menopause, and this loss is due to 
osteoclast penetration of existing trabeculae. Could the 
increased resorption surfaces seen by Nordin reflect the 
previous activity postulated by Parfitt? Clearly, addi-
tional studies are necessary, but the focus of research 
should shift from the patient with the disease (fracture) 
to the individual who loses bone at a rapid rate some 
years before the morbid event. 
Low bone mass is one of the principal determinants of 
osteoporotic fractures. Heaney, et al (pp. 333 ff.) reviewed 
the complex mechanisms responsible for determination 
of bone mass in the aging individual. Four elements are 
important: 1) peak bone mass achieved; 2) remodeling 
balance; 3) remodeling rate; and 4) time. Many factors 
may affect the first three variables to produce the bone 
mass found at any time. 
Mechanical loading, perhaps through direct or indirect 
stimulation of osteoblasts (thereby producing a positive 
remodel ing balance) may be important, both in attain-
ment of peak adult bone mass and in subsequent rates of 
loss. With age, there is a reduction of peak strains 
induced, rate of strain, and diversity of activity per-
formed. These factors may lead to a negative remodeling 
balance and bone loss. 
Remodeling rates may be determined primarily by para-
thyroid hormone secretion. In the presence of a nega-
tive remodeling balance, such as is found in aging 
individuals, an increase in remodeling rate would lead to 
more rapid loss of bone. Increased effective calcium 
intake will suppress parathyroid hormone (PTH) and, 
thus, remodel ing. It is not entirely clear whether calcium 
intake within the usually-expected range affects bone 
loss, but inadequate intake certainly could accelerate 
loss caused by other factors. Other nutrients may nega-
tively affect calcium balance as wel l , especially excessive 
intakes of protein and alcohol. 
Estrogen deficiency is associated with accelerated bone 
loss, although the mechanisms are not clear. Remodel-
ing rates are increased by estrogen withdrawal, and in 
the presence of a negative remodeling balance, more 
rapid loss would ensue. Estrogen also appears to affect 
calcium homeostatic mechanisms, which lead to more 
effective absorption from gut, renal calcium conserva-
t ion, and a blunted PTH effect. 
Calcitonin may play a role in age-related bone loss, but 
this role remains to be clearly delineated; also, accumu-
lation of structural errors,such as perforation of trabecu-
lae by excessive osteoclastic resorption (as suggested by 
Parfitt), may be important. 
Clearly, many factors are important in the determination 
of bone mass, and it is only through a better understand-
ing of these mechanisms that a rational approach to 
prevention of bone loss can be derived. 
It has generally been assumed that osteoporotic fractures 
of the vertebrae, distal radius, and hip have a similar 
pathogenesis. However, Riggs, et al (pp. 337 ff.) suggested 
that there are several osteoporotic syndromes. Type 1 
osteoporosis is associated with excessive trabecular bone 
loss and leads to vertebral collapse fractures and to Colles 
fractures, especially among women 50 to 65 years of age. 
It is postulated that estrogen deficiency leads to an 
increased bone sensitivity to the action of PTH, and that 
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this activity causes loss of bone. The calcium mobilized 
with bone loss reduces PTH secretion but not enough to 
prevent excessive bone loss. However, since serum PTH 
concentration is reduced, less 1,25(OH)2D3is synthesized 
by the kidney, and calcium malabsorption ensues. Since 
all women are estrogen-deficient after menopause, and 
no measured difference in sex hormone concentrations 
has been found between the majority who do not 
develop osteoporosis and the small group who do, Riggs 
postulated that there is some undefined intrinsic abnor-
mality of bone which predisposes to excessive loss with 
estrogen deficiency. Nordin has suggested that the osteo-
porotics have more marked calcium malabsorption, which 
should lead to increased secretion of PTH, and Riggs has 
found PTH concentrations to be low in this group, com-
pared to controls. Thus, the predisposing factors remain 
to be determined. 
Type 2 osteoporosis is associated with the loss of both 
trabecular and cortical bone, and eventually leads to hip 
and vertebral fractures. It occurs primarily in individuals 
over 75; although more common in women, it also 
affects men. It is postulated that a primary defect in 
1,25(OH)2D3 synthesis leads to calcium malabsorption 
and secondary hyperparathyroidism with increased bone 
turnover. Since there is a negative remodeling balance at 
individual sites, bone loss occurs. 
Riggs, his associates, and others have accumulated evi-
dence that the different fracture syndromes generally 
associated with osteoporosis may be due to different 
mechanisms of bone loss. This concept is important in 
designing effective programs for prophylaxis and treat-
ment. Clearly, we would not wish to introduce a therapeu-
tic program to prevent one fracture type that would lead 
to a greater risk of developing another fracture syndrome. 
The important clinical problem of steroid-induced osteo-
porosis was reviewed by Avioli (pp. 343 ff.). Glucocorti-
coids seem to produce loss of trabecular bone primarily 
and, thus, vertebral fractures. The effect is dose and time 
dependent, but it can occur with as little as 7 mg of 
prednisone a day or its equivalent. Those particularly at 
risk are growing children, postmenopausal women, and 
those receiving other drugs which may affect the skel-
eton, such as anti-convulsants. Glucocorticoids have mul-
tiple effects that are responsible for bone loss, including 
impaired calcium absorption, increased calcium excre-
tion by the kidney, and impaired osteoblast function. 
No effective means is currently available to prevent 
these complications, other than reduction in dose and 
time of administration when possible. A new glucocort i-
coid under development, Deflazacort, shows promise of 
being less deleterious to mineral homeostatis than cur-
rently available drugs. 
Prevention and Treatment 
The treatment of osteoporosis must be considered from 
the standpoint of both prevention of bone loss and ther-
apy of the patient after fracture has occurred. Lindsay 
(pp. 346 ff.) reviewed the evidencethat administration of 
estrogen can prevent loss of bone in postmenopausal 
women. This effect has been demonstrated, using tech-
niques which measure both cortical and trabecular bone. 
With therapy, bone loss can be prevented up to eight 
years, when slow loss may begin. When estrogen is wi th-
drawn, loss ensues, but it is no greater than the loss 
occurring after natural menopause. Administration of 
estrogen is also associated with less loss of height and 
fewer vertebral deformities than occur in placebo-treated 
controls. Christiansen, et al (pp. 349 ff.) also noted that a 
combination of estrogen and progesterone prevents cor-
tical bone loss. The principal problem of prophylaxis with 
estrogen is the determination of who should receive the 
drug, since it can be toxic. Christiansen has found that 
there is a population of rapid bone losers that, he pre-
dicts, will develop osteoporosis. There women have 
lower estrogen concentrations, higher serum alkaline 
phosphatase, and higher ur inary hyd roxyp ro l i ne / 
creatinine ratios than those who lose bone more slowly. 
While this problem requires additional study, these data 
provide promising leads to the development of a simple 
screening procedure to select women for prophylactic 
estrogen therapy shortly after the onset of menopause. 
Chesnut and associates (pp. 355 ff.) demonstrated that 
administration of calcitonin to patients with osteopo-
rotic fractures led to an increase in total body calcium, as 
measured by neutron activation. This increase persisted 
for 18 months, but by 26 months the rate of gain was not 
sustained; no change in regional bone mass could be 
measured by photon absorptiometry. The patients toler-
ated the calcitonin well with few adverse reactions. This 
group has also demonstrated that administration of sta-
nozolol to a similar population of postmenopausal 
osteoporotic patients was associated with a significant 
increase in total body calcium at 26 months on therapy. 
The magnitude of the increase in calcium retention 
seemed to persist throughout the study. Analysis of bio-
chemical and histologic data suggested that the effect of 
the drug was to stimulate bone formation. Transient 
elevations in SCOT were noted in some patients, as well 
as some evidence of increased facial hair, ankle edema, 
and hoarseness. Neitherstudy contained sufficient num-
bers of patients to determine whether the incidence of 
fractures was reduced. 
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Meunier, et al (pp. 360 ff.) presented data on 57 osteopo-
rotic patients treated for two years with a combination of 
sodium f luoride, calcium, and vitamin D. No control 
group was included. Fifty-six percent of the patients 
experienced relief f rom back pain after two years of 
therapy. The incidence of vertebral fracture was lower in 
the second year of treatment than in the first, and the 
mean annual increase in the radiological vertebral index 
was also lower during the second year. No significant 
changes were found in the biochemical parameters 
measured. Bone biopsies were performed before and 
after treatment i n i l patients classified as good respond-
ers; there was a marked increase in the osteoid surfaces 
and osteoblastic surfaces without an increase in the 
resorption surfaces. The increase in trabecular bone 
volume was also marked in these biopsies. The newly-
formed bone was lamellar in character. No microradio-
graphs were performed, but some evidence in the litera-
ture suggests that newly-formed bone is not as well 
calcified as normal bone. Side effects consisted of mild 
gastrointestinal irritation in 22% o f the patients and tran-
sient periarticular pain in 33%, but only 7% o f the patients 
discontinued therapy because of adverse reactions. Some 
patients treated with f luoride did not appear to respond 
to the therapy. Meunier found that some showed no 
response on formation surfaces, while others had increased 
formation surfaces but did not gain bone. The mecha-
nisms for these changes remain to be elucidated. 
Initial studies have been undertaken to evaluate the 
effect of 1,25(OH)2D3. When this drug was given in a 
preliminary study, bone volume increased significantly 
at 24 months, as measured on iliac crest biopsies. The 
calcium balance improved so that it was positive after six 
months, but subsequently a less positive balance was 
found. There appeared to be a significant decrease in 
vertebral fractures in the treated group. Additional 
studies wil l be necessary to evaluate this therapeutic 
agent in the treatment of osteoporosis. 
A new approach to the treatment of osteoporosis, the 
"ADFR" method, has been developed. Currently under 
evaluation, this method was reviewed by Frost (pp. 368 
ff.). An agent known to activate bone remodeling is 
adminstered in pulsatile fashion in order to activate a 
number o f the bone remodeling units simultaneously. A 
medication which will depress osteoclastic activity dur-
ing the resorptive phase is then administered, thus 
reducing the amount of bone removed. Subsequently, a 
free period is allowed so that the osteoblasts wil l replace 
their programmed quantum of bone. Since the osteo-
clasts have removed less bone, bone balance will be 
positive. The entire sequence can then be repeated. This 
method was developed based on the current under-
standing of bone funct ion as an organ. Preliminary data 
from animal studies appear to indicate that the sequence 
will produce its desired effect. 
Progress has been made over the past decade in our 
understanding of osteoporosis. Use o f t h e bone biopsy 
has led to a better understanding of the pathogenesis of 
age-related bone loss, although controversy still remains. 
Efforts should be focused on that period of rapid bone 
loss that occurs shortly after menopause. Many factors 
may be important in the development of maximum adult 
bone mass and its subsequent rate of loss, including 
mechanical loading, hormonal influences, and nutri t ion 
factors. These all provide ferti le areas for additional 
research during the next few years. Since the fracture 
syndromes generally associated with osteoporosis may 
be due to different pathogenic mechanisms, an approach 
to prevention and treatment may require awareness of 
this heterogeneity. The application of the ADFR theory 
may allow even further advances. As progress is made to 
identify patients who wil l subsequently be at risk of frac-
ture, a rational prophylaxis can be designed. The next 
decade should provide exciting new insights into the 
pathogenesis and treatment of osteoporosis. 
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